Childhood body mass index trajectories, adult-onset type 2 diabetes, and obesity-related cancers.


Journal

Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089

Informations de publication

Date de publication:
10 01 2023
Historique:
received: 25 03 2022
revised: 04 07 2022
accepted: 31 08 2022
pubmed: 11 10 2022
medline: 12 1 2023
entrez: 10 10 2022
Statut: ppublish

Résumé

Elevated childhood body mass index (BMI), commonly examined as a "once-only" value, increases the risk of cancer and type 2 diabetes (T2D) in adulthood. Continuous exposure to adiposity during childhood may further increase cancer risk. We examined whether longitudinal childhood BMI trajectories were associated with adult obesity-related cancer and the role of adult-onset T2D in these associations. Five sex-specific latent class BMI trajectories were generated for 301 927 children (149 325 girls) aged 6-15 years from the Copenhagen School Health Records Register. Information on obesity-related cancers and T2D was obtained from national health registers. Incidence rate ratios (IRR), cumulative incidences, and confidence intervals (CI) were estimated using Poisson regressions. Compared with the average childhood BMI trajectory (containing approximately 40% of individuals), the rate of obesity-related cancer (excluding breast cancer) increased with higher childhood BMI trajectories among women. The highest rates occurred in the overweight (IRR = 1.27, 95% CI = 1.17 to 1.38) and obesity (IRR = 1.79, 95% CI = 1.53 to 2.08) BMI trajectories. Similar patterns were observed among men. In contrast, women with the obesity childhood BMI trajectory had the lowest rate of pre- and postmenopausal breast cancer (IRR = 0.59, 95% CI = 0.43 to 0.80, and IRR = 0.41, 95% CI = 0.30 to 0.57, respectively). For all trajectories, the cumulative risk of obesity-related cancer increased with adult-onset T2D. Consistent childhood overweight or obesity may increase the rates of adult obesity-related cancer and decrease the rates of breast cancer. Adult-onset T2D conferred additional risk for obesity-related cancer, but the effect did not differ across childhood BMI trajectories.

Sections du résumé

BACKGROUND
Elevated childhood body mass index (BMI), commonly examined as a "once-only" value, increases the risk of cancer and type 2 diabetes (T2D) in adulthood. Continuous exposure to adiposity during childhood may further increase cancer risk. We examined whether longitudinal childhood BMI trajectories were associated with adult obesity-related cancer and the role of adult-onset T2D in these associations.
METHODS
Five sex-specific latent class BMI trajectories were generated for 301 927 children (149 325 girls) aged 6-15 years from the Copenhagen School Health Records Register. Information on obesity-related cancers and T2D was obtained from national health registers. Incidence rate ratios (IRR), cumulative incidences, and confidence intervals (CI) were estimated using Poisson regressions.
RESULTS
Compared with the average childhood BMI trajectory (containing approximately 40% of individuals), the rate of obesity-related cancer (excluding breast cancer) increased with higher childhood BMI trajectories among women. The highest rates occurred in the overweight (IRR = 1.27, 95% CI = 1.17 to 1.38) and obesity (IRR = 1.79, 95% CI = 1.53 to 2.08) BMI trajectories. Similar patterns were observed among men. In contrast, women with the obesity childhood BMI trajectory had the lowest rate of pre- and postmenopausal breast cancer (IRR = 0.59, 95% CI = 0.43 to 0.80, and IRR = 0.41, 95% CI = 0.30 to 0.57, respectively). For all trajectories, the cumulative risk of obesity-related cancer increased with adult-onset T2D.
CONCLUSION
Consistent childhood overweight or obesity may increase the rates of adult obesity-related cancer and decrease the rates of breast cancer. Adult-onset T2D conferred additional risk for obesity-related cancer, but the effect did not differ across childhood BMI trajectories.

Identifiants

pubmed: 36214627
pii: 6754822
doi: 10.1093/jnci/djac192
pmc: PMC9830482
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-51

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

Int J Cancer. 2017 May 1;140(9):2003-2014
pubmed: 28133728
Am J Prev Med. 2014 Mar;46(3 Suppl 1):S52-64
pubmed: 24512931
Int J Obes (Lond). 2016 Sep;40(9):1376-83
pubmed: 27168050
Wiley Interdiscip Rev Dev Biol. 2012 Jul-Aug;1(4):533-57
pubmed: 22844349
PLoS Med. 2016 Aug 16;13(8):e1002081
pubmed: 27529652
BMJ Open. 2018 Jul 7;8(7):e020683
pubmed: 29982203
Scand J Public Health. 2011 Jul;39(7 Suppl):87-90
pubmed: 21775361
Atherosclerosis. 2020 Dec;314:10-17
pubmed: 33129081
Ann Med. 2015 Feb;47(1):34-9
pubmed: 25307361
Diabetes Care. 2021 Apr;44(4):901-907
pubmed: 33509931
Int J Epidemiol. 2012 Jun;41(3):861-70
pubmed: 22253319
CA Cancer J Clin. 2010 Jul-Aug;60(4):207-21
pubmed: 20554718
Diabetologia. 2012 Jun;55(6):1607-18
pubmed: 22476947
BMJ. 2015 Jan 02;350:g7607
pubmed: 25555821
Obesity (Silver Spring). 2017 May;25(5):965-971
pubmed: 28345789
Lancet Diabetes Endocrinol. 2018 Feb;6(2):95-104
pubmed: 29195904
Br J Cancer. 2020 May;122(10):1552-1561
pubmed: 32203222
Int J Epidemiol. 2009 Jun;38(3):656-62
pubmed: 18719090
Vital Health Stat 11. 2002 May;(246):1-190
pubmed: 12043359
Diabetes. 2020 Jul;69(7):1588-1596
pubmed: 32349989
Nat Rev Cancer. 2015 Aug;15(8):484-98
pubmed: 26205341
Int J Obes (Lond). 2020 Jul;44(7):1546-1560
pubmed: 31974406
Scand J Public Health. 2011 Jul;39(7 Suppl):42-5
pubmed: 21775350
MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):161-165
pubmed: 32053581
Eur J Cancer Prev. 2013 Jan;22(1):29-37
pubmed: 22694827
Int J Cancer. 2016 May 15;138(10):2383-95
pubmed: 26704725
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Annu Rev Clin Psychol. 2010;6:109-38
pubmed: 20192788
Epidemiology. 2009 Jul;20(4):496-9
pubmed: 19525686
Int J Cancer. 2021 Oct 1;149(7):1421-1425
pubmed: 34004046
Int J Cancer. 2020 Feb 1;146(3):712-719
pubmed: 30927373
Obes Rev. 2019 Jul;20(7):998-1015
pubmed: 30942535
Cancer Res. 2010 Jul 1;70(13):5419-29
pubmed: 20530677
Diabetes Care. 2004 Jul;27(7):1798-811
pubmed: 15220270
Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):690-7
pubmed: 25777804
Eur J Cancer. 2014 Aug;50(12):2119-25
pubmed: 24930060
J Natl Cancer Inst. 2003 Aug 20;95(16):1244-8
pubmed: 12928351
Lancet Oncol. 2015 Jan;16(1):36-46
pubmed: 25467404
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Am J Hum Biol. 2020 Jul;32(4):e23378
pubmed: 31876344

Auteurs

Britt W Jensen (BW)

Center for Clinical Research and Prevention, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.

Julie Aarestrup (J)

Center for Clinical Research and Prevention, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.

Kim Blond (K)

Center for Clinical Research and Prevention, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.

Marit E Jørgensen (ME)

Clinical Epidemiological Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
Steno Diabetes Center Greenland, Nuuk, Greenland.
National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.

Andrew G Renehan (AG)

Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Dorte Vistisen (D)

Clinical Epidemiological Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Jennifer L Baker (JL)

Center for Clinical Research and Prevention, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH